Use of bisphosphonates in a case of Perthes disease
Abstract
Bisphosphonates are a group of drugs that have been used extensively for more than 10 years to treat adults with osteoporosis. Use of bisphosphonates in pediatrics has generally been confined to conditions such as osteogenesis imperfecta or other conditions with bone density problems. Bisphosphonates increase bone density, bone mineral content, and strength; improve mobility; reduce fracture rates; and are effective agents in combating bone pain. Bisphosphonates inhibit osteoclastic action, thereby increasing bone density (Rauch & Glorieux 2004). Recently there has been interest in the effect of bisphosphonates in localized disorders of bone, including avascular necrosis. The third-generation bisphosphonate zoledonic acid is currently being explored as a treatment for children presenting with Perthes disease at the Children's Hospital at Westmead, Sydney, Australia, and this is a report of that experience.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Development of a crushable foam model for human trabecular bone
- Data-driven motion compensation in HR-pQCT.
- Modeling of structure, quality, and function in the orthodontic patient
- Exploring the mechanism of Heidihuang Pill in the treatment of osteoporosis based on network pharmacology, molecular docking, and experimental validation
- Effect of fabric on the accuracy of computed tomography-based finite element analyses of the vertebra
- Use of interventions involving virtual reality tasks during the climacteric: a systematic review
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.